128 related articles for article (PubMed ID: 36282014)
1. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases.
Dispenzieri A; Zonder J; Hoffman J; Wong SW; Liedtke M; Abonour R; D'Souza A; Lee C; Cote S; Potluri R; Ammann E; Tran N; Lam A; Nair S
Amyloid; 2023 Jun; 30(2):161-168. PubMed ID: 36282014
[TBL] [Abstract][Full Text] [Related]
2. Overall survival, costs, and healthcare resource use by line of therapy in Medicare patients with newly diagnosed metastatic urothelial carcinoma.
Aly A; Johnson C; Yang S; Botteman MF; Rao S; Hussain A
J Med Econ; 2019 Jul; 22(7):662-670. PubMed ID: 30836812
[No Abstract] [Full Text] [Related]
3. Treatment patterns and health care resource utilization among patients with relapsed/refractory systemic light chain amyloidosis.
Hari P; Lin HM; Asche CV; Ren J; Yong C; Luptakova K; Faller DV; Sanchorawala V
Amyloid; 2018 Mar; 25(1):1-7. PubMed ID: 29303358
[TBL] [Abstract][Full Text] [Related]
4. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis.
Blair HA
Drugs; 2022 Apr; 82(6):683-690. PubMed ID: 35416593
[TBL] [Abstract][Full Text] [Related]
5. Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study.
Jaccard A; Bridoux F; Roeloffzen W; Minnema MC; Bergantim R; Hájek R; João C; Cibeira MT; Palladini G; Schönland S; Merlini G; Milani P; Dimopoulos MA; Ravichandran S; Hegenbart U; Agis H; Gros B; Asra A; Magarotto V; Cheliotis G; Psarros G; Sonneveld P; Wechalekar A; Kastritis E
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):e205-e216. PubMed ID: 38453615
[TBL] [Abstract][Full Text] [Related]
6. Incidence rate of hospitalization and mortality in the first year following initial diagnosis of cardiac amyloidosis in the US claims databases.
Wang L; Swerdel JN; Weaver J; Weiss B; Pan G; Yuan Z; DiBattiste PM
Curr Med Res Opin; 2021 Aug; 37(8):1275-1281. PubMed ID: 33830834
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs in amyloid light-chain amyloidosis: a real-world study using US claims data.
Quock TP; Yan T; Chang E; Guthrie S; Broder MS
J Comp Eff Res; 2018 Jun; 7(6):549-559. PubMed ID: 29390860
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib with dexamethasone as first-line treatment for AL amyloidosis with renal involvement.
Huang X; Wang Q; Chen W; Ren G; Liu Z
Amyloid; 2016; 23(1):51-7. PubMed ID: 26862817
[TBL] [Abstract][Full Text] [Related]
9. Real-World Analysis of Treatment Patterns, Healthcare Utilization, Costs, and Mortality Among People with Biliary Tract Cancers in the USA.
Healey MJ; Seal B; Princic N; Black D; Malangone-Monaco E; Azad NS; Smoot RL
Adv Ther; 2022 Dec; 39(12):5530-5545. PubMed ID: 36241962
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic delay and characterization of the clinical prodrome in AL amyloidosis among 1523 US adults diagnosed between 2001 and 2019.
Hester LL; Gifkins DM; M Bellew K; Vermeulen J; Schecter JM; Strony J; Dishy V; Weiss BM
Eur J Haematol; 2021 Oct; 107(4):428-435. PubMed ID: 34137077
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and clinical outcomes of light-chain amyloidosis in Sweden: A nationwide population-based study.
Mellqvist UH; Cai Q; Hester LL; Grövdal M; Börsum J; Rahman I; Ammann EM; Hansson M
Eur J Haematol; 2023 Nov; 111(5):697-705. PubMed ID: 37533343
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of treatment outcomes in 45 patients with cardiac light-chain amyloidosis: a single-center experience in Japan.
Fuchida SI; Ide D; Taminishi-Katsuragawa Y; Suga T; Matsui-Maegawa S; Maruyama N; Iwamura Y; Kitamura Y; Okawa Y; Okano A; Hatsuse M; Murakami S; Shimazaki C
Int J Hematol; 2020 Jun; 111(6):803-811. PubMed ID: 32020505
[TBL] [Abstract][Full Text] [Related]
14. Successful treatment of renal light chain (AL) amyloidosis with bortezomib and dexamethasone (VD).
Huang B; Li J; Xu X; Zheng D; Zhou Z; Liu J
Pathol Biol (Paris); 2015 Feb; 63(1):17-20. PubMed ID: 25455933
[TBL] [Abstract][Full Text] [Related]
15. [Treatment strategy for immunoglobulin light chain amyloidosis].
Fuchida SI
Rinsho Ketsueki; 2021; 62(8):1160-1166. PubMed ID: 34497203
[TBL] [Abstract][Full Text] [Related]
16. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
17. Treatment patterns and outcomes in light chain amyloidosis: An institutional registry of amyloidosis report in Argentina.
Posadas-Martinez ML; Aguirre MA; Brulc E; Saez MS; Sorroche P; Machnicki G; Fernandez M; Nucifora EM
PLoS One; 2022; 17(10):e0274578. PubMed ID: 36301970
[TBL] [Abstract][Full Text] [Related]
18. Doxycycline Combined With Bortezomib-Cyclophosphamide-Dexamethasone Chemotherapy for Newly Diagnosed Cardiac Light-Chain Amyloidosis: A Multicenter Randomized Controlled Trial.
Shen KN; Fu WJ; Wu Y; Dong YJ; Huang ZX; Wei YQ; Li CR; Sun CY; Chen Y; Miao HL; Zhang YL; Cao XX; Zhou DB; Li J
Circulation; 2022 Jan; 145(1):8-17. PubMed ID: 34503349
[TBL] [Abstract][Full Text] [Related]
19. Clinical features, laboratory characteristics and outcomes of patients with renal versus cardiac light chain amyloidosis.
Sidana S; Tandon N; Gertz MA; Dispenzieri A; Ramirez-Alvarado M; Murray DL; Kourelis TV; Buadi FK; Kapoor P; Gonsalves W; Warsame R; Lacy MQ; Kyle RA; Rajkumar SV; Kumar SK; Leung N
Br J Haematol; 2019 May; 185(4):701-707. PubMed ID: 30836444
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of cyclophosphamide, thalidomide and dexamethasone (CTD) versus bortezomib and dexamethasone (BDex) in light-chain amyloidosis.
Liu B; Wang Y; Ning X; Bai M; Wang D; Zhao J; Zhou M; Sun S
Curr Probl Cancer; 2021 Apr; 45(2):100669. PubMed ID: 33127168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
